Earnings call transcript: Dr. Reddy’s Q4 2026 misses earnings expectations By Investing.com

Dr. Reddy’s Q4 FY2026 earnings missed expectations sharply, with EPS of $0.0616 versus $0.1255 forecast and revenue of $789.1 million versus $893.0 million, while gross margin fell 760 bps YoY to 48%. The miss was driven by lenalidomide self-stock adjustment, price erosion in generics, and one-off charges, although management reiterated FY2027 margin improvement above 50% and double-digit ex-lenalidomide growth. Shares still rose 1.48% premarket, reflecting investor focus on semaglutide, biosimilars, and other pipeline launches.

Analysis

The core takeaway is not the earnings miss; it’s that the market is starting to look through a legacy U.S. generic step-down and assign value to the pipeline/cash-flow swap that follows. The near-term pain from lenalidomide is temporary, but it also exposed how concentrated the current U.S. profit pool remains, which means every incremental unit of semaglutide or biosimilar success has an outsized effect on the equity story. That creates a cleaner setup for a re-rating only if management can prove the new mix shows up in gross margin before the legacy decay fully normalizes.

The second-order winner is less obvious: contract manufacturers, device/input suppliers, and biosimilar partners tied to the semaglutide and abatacept ramps stand to benefit from a multi-quarter buildout in working capital and validation spend. The weak point is the partner-dependent regulatory pathway in Brazil and the U.S. biologics timeline, where any inspection delay pushes monetization into FY28 and increases the probability the street discounts the pipeline at a steeper haircut. In other words, the stock is being asked to bridge a 12–18 month gap with narrative and not yet with earnings.

Consensus is likely underestimating how much of the FY27 margin expansion can be funded by mix rather than cost cuts. If semaglutide scales in the expected 3–4 million pens/quarter range, the contribution margin can offset a meaningful chunk of generic erosion even if operating expenses stay flat in nominal terms; that makes the 25% margin target achievable earlier than modelled, but only in a good-regulatory / good-launch case. The converse is that if Brazil slips again or Canada pricing compresses faster than expected, the market will punish the multiple immediately because the dividend and cash balance do not fully protect against an earnings-duration reset.

Key Decisions for Investors

• Long RDY on a 3–6 month horizon only on dips into weakness after the print; use a tiered entry and keep a tight stop if U.S. generic ex-len growth fails to re-accelerate in the next quarter. Upside is a multiple re-rating on semaglutide/abatacept proof points; downside is another quarter of mix pressure and delayed pipeline monetization.
• Pair trade: long RDY / short ALVOW for 6–12 months. RDY has more visible near-term commercialization cadence and broader geographic optionality, while ALVOW is more exposed to biologics execution risk and partner dependence; the pair works if semaglutide or abatacept milestones arrive on time.
• Sell downside via RDY put spreads 2–4 months out if implied volatility stays elevated post-earnings. The stock already has cash support and a dividend floor, but event risk around Brazil/FDA timing makes outright shorting poor risk/reward.
• Watch IMMP as a relative loser on the partner-trial write-down signal; if more pipeline pruning follows, the market will mark down partnered pre-commercial assets across the group. Prefer reducing exposure to development-stage names with binary readouts over the next 2 quarters.
• Add a tactical long in healthcare supply-chain beneficiaries only if RDY confirms launch spend acceleration next call; the better expression is through inputs/CMOs rather than chasing RDY upside before execution is visible.